KP 106
Alternative Names: KP106Latest Information Update: 26 Feb 2023
Price :
$50 *
At a glance
- Originator KemPharm
- Developer Zevra Therapeutics
- Class Amphetamines
- Mechanism of Action Adrenergic receptor agonists; Central nervous system stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Attention-deficit hyperactivity disorder
Most Recent Events
- 22 Feb 2023 KemPharm is now called Zevra Therapeutics
- 01 Aug 2013 Discontinued - Phase-I for Attention-deficit hyperactivity disorder in USA (PO)
- 30 Aug 2011 KP 106 is available for licensing as of 30 Aug 2011.